AMGEN Inc
NASDAQ: AMGN
$282.87
+$2.80 (+1.0%)
Closing Price on November 29, 2024
AMGN Articles
After today’s close, we’ll be getting earnings out of biotech giant Amgen Inc. (NASDAQ: AMGN). It’s amazing how the company’s strong osteoporosis data has suddenly gotten the company out...
Published:
Last Updated:
These are not all of the upgrades or positive calls we have seen, but these are some calls moving shares this Monday morning: AFLAC (AFL) Raised to Outperform at Raymond James. Amgen (AMGN) Raised to...
Published:
We saw another exciting week full of news for key developments in drug stocks, biotech stocks, medical device stocks, and other companies involved in various aspects of health care and medicine. ...
Published:
Based on data from Nasdaq as of June 13, short sellers made heavy bets against tech stocks. Many investors clearly think the sector is not immune from the current economic downturn. The short...
Published:
Shares of Amgen Inc. (NASDAQ: AMGN) are seeing a small gain in after-hours trading. The troubled biotech giant announced that findings from its head-to-head, double-blind trial comparing the...
Published:
Last Updated:
Amgen (AMGN) adjusted earnings per share of $1.12 for the first quarter of 2008, an increase of 4 % compared to $1.08 for the first quarter of 2007. Adjusted net income decreased 4 % to $1.218...
Published:
This week felt like a yo-yo of volatility, and frankly that makes it even better that it was a 4-day work week for the stock market. Despite the huge rally today that was led by the financials,...
Published:
Last Updated:
These are the top analyst calls we are focusing on early this Thursday morning in pre-market trading: Abbott Laboratories (NYSE: ABT) Raised To Outperform at Wachovia. Altria (NYSE: MO) started as...
Published:
It almost seems that no matter what happens, there are always some major companies whose shares just won’t recover when the broad market recovers. Sometimes it’s on news, and sometimes it is...
Published:
Biotech’s are sliding along with all the others today. A look at the highlights and outliers: Amgen (NASDAQ: AMGN) and Wyeth (NYSE: WYE) announced that arthritis and psoriasis drug Enbrel will now...
Published:
According to Reuters, regulators unveiled a plan to toughen rules for mortgage brokers. Reuters writes that Yahoo! (YHOO) and Microsoft (MSFT) have begiin informal discussion about the buy-out....
Published:
Two of the best-selling drugs in the US are Procrit from Johnson & Johnson (NYSE: JNJ) and Aranesp from Amgen (NASDAQ:AMGN). The products treat anemia in patients with kidney dialysis issues....
Published:
According to Reuters, weak confidence and rising prices are fuelin stagflation fears. Reuters writes that the long fight between Microsoft (MSFT) and Yahoo! (YHOO) over a takeover will help Google...
Published:
Below are some of the top issues affecting biotech shares today: AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company developing iron compounds to treat anemia, saw shares rise 4%...
Published:
Amgen Inc. (NASDAQ: AMGN) has announced earnings after the company released some positive data this morning. The troubled biotech giant posted $1.00 EPS on a 2% drop in revenues to $3.7 Billion. ...
Published:
Last Updated: